Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

NCT05468242 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Stage III Non-small Cell Lung Cancer

Interventions

DRUG: Neoadjuvant chemo-immunotherapy
DRUG: Bevacizumab
RADIATION: Radiotherapy
DRUG: Tislelizumab

Sponsor

Sun Yat-sen University